Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 2/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 5/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
| ▸ | ATR | Q13535 | 1/20 | 0.31 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.31 |
| ▸ | AKT1 | P31749 | 1/20 | 0.30 |
| ▸ | KDM4A | O75164 | 1/20 | 0.30 |
| ▸ | KDM5A | P29375 | 1/20 | 0.30 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.30 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12869875 | 0.85 | SCN9A (0.38) | DRD1SCN9A | |
| SCHEMBL19205767 | 0.71 | DRD1 (0.47) | DRD1SCN9AMAPK14KDM5AKDM4C | |
| SCHEMBL25144315 | 0.71 | SCN9A (0.42) | DRD1SCN9A | |
| SCHEMBL20843895 | 0.69 | DRD1 (0.31) | DRD1 | |
| SCHEMBL20548183 | 0.68 | SCN9A (0.37) | DRD1SCN9A | |
| SCHEMBL12869812 | 0.68 | DRD1 (0.39) | DRD1SCN9A | |
| SCHEMBL13045975 | 0.67 | DRD1 (0.46) | DRD1KDM5AKDM4CKDM5B | |
| SCHEMBL21858863 | 0.67 | CYP17A1 (0.40) | DRD1KDM4AKDM4C | |
| SCHEMBL486116 | 0.67 | FFAR1 (0.31) | — | |
| SCHEMBL4476413 | 0.66 | DRD1 (0.48) | DRD1MAPK14KDM4AKDM5AKDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2411388-A2 | PROCESS FOR THE PRODUCTION OF FUSED, TRICYCLIC SULFONAMIDES | Elan Pharmaceuticals Inc. (US) | 2012-02-01 | — | — | EP | disclosed |
| US-20110034691-A1 | Process for the Production of Fused, Tricyclic Sulfonamides | ELAN PHARMACEUTICALS, INC. | 2011-02-10 | — | — | US | disclosed |
| US-20110034691-A1 | Process for the Production of Fused, Tricyclic Sulfonamides | ELAN PHARMACEUTICALS, INC. | 2011-02-10 | — | — | US | disclosed |
| US-20110034691-A1 | Process for the Production of Fused, Tricyclic Sulfonamides | ELAN PHARMACEUTICALS, INC. | 2011-02-10 | — | — | US | disclosed |
| WO-2010111418-A2 | PROCESS FOR THE PRODUCTION OF FUSED, TRICYCLIC SULFONAMIDES | ELAN PHARMACEUTICALS, INC. (US) | 2010-09-30 | — | — | WO | disclosed |
| WO-2010111418-A2 | PROCESS FOR THE PRODUCTION OF FUSED, TRICYCLIC SULFONAMIDES | ELAN PHARMACEUTICALS, INC. (US) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034691-A1 | Process for the Production of Fused, Tricyclic Sulfonamides | CBR3, DRD4, SBDS | DRD1 10/4885SCN9A 1991/4885MAPK14 2031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.